The Von Willebrand Factor (VWF) is a glycoprotein found in the blood that plays an important role in hemostasis. It is a key component of the coagulation cascade, and is essential for the formation of a stable platelet plug during the clotting process. VWF is also involved in the adhesion of platelets to the site of injury, and is important for the maintenance of normal platelet function. VWF is used in the treatment of several hematological disorders, including von Willebrand disease, thrombocytopenia, and hemophilia. VWF is available in both recombinant and plasma-derived forms, and is used in the form of concentrates, injections, and topical creams. The VWF market is a rapidly growing segment of the hematological drugs market, driven by the increasing prevalence of hematological disorders and the growing demand for effective treatments. The market is expected to continue to grow in the coming years, driven by the development of new treatments and the increasing availability of VWF products. Some of the major companies in the VWF market include CSL Behring, Grifols, Octapharma, Kedrion, and Shire. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
